ARS Pharmaceuticals Announces PDUFA Date Extension for neffy ® (epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news